Acute Myelogenous Leukemia (AML) Support Group
Acute myelogenous leukemia (AML), also known as acute myeloid leukemia, is a cancer of the myeloid line of blood cells. Patients with AML usually present with symptoms such as fatigue, bleeding, infection, prompting medical attention. An abnormal blood test reading will then result in further testing in a hospital with a hematologist to determine AML.
We are scheduled for the first dose of the clinical trial preemptive donor lymphocyte infusion that tony signed up for, this Monday at noon. We have mixed emotions as we know the lymph count is low after transplsnt and this will help w viral protection and establishing the gVL effect but could also increase risk of GVh or exasperate any current gvh. All we know Is the reward outweighs the risk, as we know we never EVER want to face leukemia again and if this "in theory" helps, then we want to do it!
Praying he tolerates the first dose well and the cells get along harmoniously with tonys body, as well as circulate and do any "seek and destroy missions" they are supposed to!
Praying he tolerates the first dose well and the cells get along harmoniously with tonys body, as well as circulate and do any "seek and destroy missions" they are supposed to!
I was treated at Sloan. Who is your husband's doctor?
Cliff
Everyone please pray for good land this week and good MRI results, dear God please
Praying for Tony....
Lora
Great doctors. My leukemia doctor was Dr. Joseph Jurcic, who left MSKCC to head up the leukemia service at Columbia Presbyterian. My transplant doctor is Dr. Esperanza Papadopoulos. I love her. That's it with specific doctors, although I have seen people in nephrology and pulmonary.,
Be well,
Cliff
[url]http://www.9news.com.au/health/2014/11/14/15/05/qld-scientists-make-leukaemia-breakthrough[/url]
3:01pm November 14, 2014
[B][SIZE="4"]Qld scientists make leukaemia breakthrough[/SIZE][/B]
Australian researchers have made a breakthrough in the treatment of leukaemia patients undergoing bone marrow transplants, finding a way to reduce the incidence of a potentially fatal complication.
The researchers say their discovery will change international practice for the treatment of leukaemia patients undergoing bone marrow transplants.
In trials at Brisbane's QIMR Berghofer Medical Research Institute and the Royal Brisbane and Women's Hospital, researchers have made significant gains in reducing the incidence of "acute graft versus host disease", a potentially fatal complication that can arise from stem cell transplants.
They did this by adding the drug [B]Tocilizumab[/B] - currently approved for use treating rheumatoid arthritis - to the transplant medication regime.
The incidence of acute GVHD was reduced from the usual 50 per cent, to 12 per cent of transplant patients in the trial, they said.
Severe cases - which often result in death - were reduced from 21 per cent to four per cent.
Queensland Health Minister Lawrence Springborg has praised the outstanding research work.
"We all stand to gain from advances in medical research, and yet again QIMR Berghofer is producing results that add to the world's knowledge and change lives," he said.
A phase three study now underway will be the final test before the addition of [B]Tocilizumab[/B] to the GVHD prevention regime is registered and adopted in clinical practice.
AAP 2014[/QUOTE]